Goldman Sachs Group Inc Lineage Cell Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 144,676 shares of LCTX stock, worth $274,884. This represents 0.0% of its overall portfolio holdings.

Number of Shares

144,676

Previous 180,189 19.71%

Holding current value

$274,884

Previous $163,000 53.37%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$0.87 - $1.79 $30,896 - $63,568	-35,513 Reduced 19.71%	144,676 $250,000
Q2 2025 Aug 14, 2025	SELL	$0.39 - $1.13 $66,266 - $192,002	-169,914 Reduced 48.53%	180,189 $163,000
Q1 2025 May 09, 2025	SELL	$0.45 - $0.72 $15,733 - $25,173	-34,963 Reduced 9.08%	350,103 $157,000
Q4 2024 Feb 11, 2025	BUY	$0.5 - $0.95 $70,421 - $133,799	140,842 Added 57.67%	385,066 $192,000
Q3 2024 Nov 14, 2024	BUY	$0.8 - $1.12 $63,712 - $89,196	79,640 Added 48.39%	244,224 $222,000

Q2 2024 Aug 13, 2024	BUY	$0.89 - $1.47 $122,846 - $202,904	138,030 Added 519.81%	164,584 $164,000
Q1 2024 May 15, 2024	SELL	$0.86 - $1.48 $9,367 - $16,121	-10,893 Reduced 29.09%	26,554 $39,000
Q4 2023 Feb 13, 2024	BUY	$0.91 - $1.35 $6,876 - $10,201	7,557 Added 25.28%	37,447 $40,000
Q3 2023 May 14, 2024	SELL	$1.16 - $1.53 $8,766 - $11,562	-7,557 Reduced 20.18%	29,890 $35,000
Q3 2023 Nov 14, 2023	BUY	$1.16 - $1.53 $3,909 - $5,156	3,370 Added 12.71%	29,890 $35,000
Q2 2023 May 14, 2024	SELL	$1.26 - $1.53 $319,093 - $387,470	-253,249 Reduced 90.52%	26,520 $37,000
Q2 2023 Aug 14, 2023	SELL	$1.26 - $1.53 $319,093 - $387,470	-253,249 Reduced 90.52%	26,520 $37,000
Q1 2023 May 14, 2024	BUY	$1.2 - $1.53 $318,828 - $406,505	265,690 Added 1887.14%	279,769 $419,000
Q1 2023 May 11, 2023	BUY	$1.2 - $1.53 $318,828 - $406,505	265,690 Added 1887.14%	279,769 $419,000
Q4 2022 May 14, 2024	SELL	$1.02 - $1.5 $1,421 - $2,091	-1,394 Reduced 9.01%	14,079 $16,000
Q4 2022 Feb 13, 2023	SELL	$1.02 - $1.5 $1,421 - $2,091	-1,394 Reduced 9.01%	14,079 $16,000
Q3 2022 May 14, 2024	SELL	$1.13 - $1.77 $73,106 - $114,511	-64,696 Reduced 80.7%	15,473 $17,000
Q3 2022 Nov 10, 2022	SELL	$1.13 - $1.77 $73,106 - $114,511	-64,696 Reduced 80.7%	15,473 $17,000
Q2 2022 May 14, 2024	BUY	$1.12 - $1.61 $47,848 - $68,782	42,722 Added 114.09%	80,169 $127,000
Q2 2022 Aug 15, 2022	SELL	$1.12 - $1.61 $52,934 - $76,093	-47,263 Reduced 37.09%	80,169 $127,000
Q1 2022 May 16, 2022	BUY	$1.21 - $2.48 $34,815 - $71,357	28,773 Added 29.16%	127,432 $196,000
Q4 2021 Feb 14, 2022	BUY	$1.84 - $2.68 $2,921 - $4,255	1,588 Added 1.64%	98,659 $242,000
Q3 2021 Nov 10, 2021	BUY	$2.26 - $2.86 $219,380 - $277,623	97,071 New	97,071 $245,000

Others Institutions Holding LCTX

# of Institutions

128

Shares Held

96M

Call Options Held

251K

Put Options Held

50K

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $323M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Lineage Cell Therapeutics, Inc. Transaction History